贫血患者血清红细胞生成素浓度的测定及临床意义

THE DETERMINATION OF SERUM ERYTHROPOIETIN IN PATIENTS WITH ANEMIA AND ITS CLINICAL SIGNIFICANCE

用小鼠胎肝细胞体外血浆凝块培养红系集落(Erythroid colong formig unit inculturc,E-CFUc)方法,以红细胞生成素(Erythropoietin,EPO)850323为标准试剂,测定正常人、贫血病人血清EPO浓度。实验用妊娠13～15d小鼠胎肝细胞。血清均经透析处理,培养液中加量最大不超过10％。EPO(850323)在培养液中浓度为2.5～100mU/ml。血清EPO(mU/ml)测定结果:28例正常人为48.O±17.7,12例再生障碍性贫血病人为946～>10000,1例巨幼细胞性贫血病人为500,1例缺铁性贫血病人为400和18例慢性肾功能衰竭病人则为94.2±87.6。结果表明:贫血病因对血清EPO浓度有影响。

Erythroid colony formation in plasma clots has been used for determining erythropoietin (EPO) concentration in serum. In this study 13-l5 day gestation fetal mouse liver was used for target cells. Sera from normal humans and anemio patients were dialyzed against distilled water at 4℃ for 3 days. The serum to be tested was added to the medium to a maxium of 10% by volume. EPO (850323) was taken as a reference standard, its concentration in the medium was within a dgoe range of 2.6 to 100mU/ml. Eesults showed that EPO concentrations in aplastie anemia (12 oases), iron-deficiency anemia (lease), megaloblastio anemia (1 case) were 916 to >10 000, 400 and 600 mil/ml respectively. All were significantly higher than 48.0±17.7mU/ml in normal humans (28 cases). In chronic renal failure (18 cases), it was 94.2±87.6mU/ml. This suggests that etiology of anemia affects serum EPO levels.